Actively Recruiting
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
Led by Eli Lilly and Company · Updated on 2026-03-05
120
Participants Needed
3
Research Sites
35 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
CONDITIONS
Official Title
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a hemoglobin A1c level of less than 6.5 percent (%) at screening.
- Have a body mass index (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening
- Participants assigned male or female at birth who are individuals of childbearing potential must use contraception consistent with local regulations during the study.
You will not qualify if you...
- Have obesity caused by endocrine disorders such as Cushing's syndrome or Prader Willi syndrome.
- Have supine systolic blood pressure of 160 mmHg or greater at screening.
- Have supine diastolic blood pressure of 100 mmHg or greater at screening.
- Have resting pulse rate greater than 95 beats per minute or less than 45 beats per minute at screening.
- Have had myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, transient ischemic attack, cerebrovascular accident, or decompensated congestive heart failure within 6 months before screening.
- Have New York Heart Association Class III or IV heart failure.
- Have serum triglyceride levels of 5 mmol/L (442 mg/dL) or greater at screening.
- Have used glucagon-like peptide-1 (GLP-1) analogs or related drugs within 3 months before screening.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States, 32117
Actively Recruiting
2
Fortrea Clinical Research Unit
Dallas, Texas, United States, 75247
Actively Recruiting
3
Fortrea Clinical Research Unit
Madison, Wisconsin, United States, 53704
Completed
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here